NXL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NX

Mkt Cap

$2.4M

Volume

20.95K

Next Earnings

November 13th

Loading chart

NX

NXLNexalin Technology, Inc. Common Stock

NXL

Pay with—

Available Balance0.00

NX

Mkt Cap

$2.6M

Volume

20.95K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and InsomniaNexalin Technology announced the issuance of U.S. Patent No. 12,629,519 covering transcranial alternating current dynamic frequency stimulation methods for anxiety, depression, and insomnia, providing intellectual property protection through 2042. The patent strengthens the company's competitive position in non-invasive deep-brain neurostimulation and supports its HALO™ Clarity platform and Nexalin NeuroCare™ virtual clinic strategy.GlobeNewswire Inc. · Jun 4, 2026

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsNexalin announced a peer-reviewed study published in BMC Psychiatry demonstrating that its DIFS 77.5 Hz high-gamma neurostimulation technology produced statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents. The pilot study of six patients showed clinical improvements with measurable changes in brain-network activity, supporting the company's non-invasive neurostimulation platform. The findings add to Nexalin's growing body of evidence across multiple CNS indications including insomnia, depression, TBI, PTSD, Alzheimer's disease, and ADHD.GlobeNewswire Inc. · Apr 9, 2026

Nexalin Technology Announces Attendance at the 2025 Maxim Growth SummitNexalin Technology, a neurostimulation company, will participate in the 2025 Maxim Growth Summit, showcasing its non-invasive brain stimulation technology for mental health treatment.GlobeNewswire Inc. · Oct 10, 2025

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public OfferingNexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, announced the closing of a $5.0 million public offering of its common stock.GlobeNewswire Inc. · May 6, 2025

Nexalin Appointed as Industry Co-Chair of National TBI Registry CoalitionNexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has been appointed as the Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment reflects Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders.GlobeNewswire Inc. · Feb 10, 2025

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23Nexalin Technology, Inc. is hosting a webinar to discuss its non-invasive, frequency-based deep brain stimulation device and progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. The company's solutions have shown clinically meaningful improvements in treating conditions like insomnia, PTSD, and traumatic brain injuries, positioning Nexalin as an emerging leader in a growing market.GlobeNewswire Inc. · Jan 23, 2025

Nexalin Technology Completes Phase 1of its Innovative Virtual ClinicNexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has launched Phase 1 of its proprietary virtual clinic. The clinic will utilize AI, Electronic Data Capture (EDC), and Patient Monitoring System (PMS) to provide a virtual treatment experience for patients while enabling real-time data acquisition and analysis.GlobeNewswire Inc. · Dec 23, 2024

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation MarketA new peer-reviewed publication validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) technology, highlighting its ability to non-invasively treat challenging psychiatric conditions and its potential to become a cornerstone in mental health treatment.GlobeNewswire Inc. · Nov 26, 2024

Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsNexalin Technology, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement, a significant milestone as the company continues to advance its mission of bringing non-invasive neurostimulation treatments for mental health and neurological disorders.GlobeNewswire Inc. · Nov 1, 2024

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VANexalin Technology announces a new clinical trial in collaboration with UC San Diego to evaluate the effectiveness of its Gen-3 Halo headset in treating veterans with mild traumatic brain injury (mTBI) using a virtual clinic model.GlobeNewswire Inc. · Oct 22, 2024

to start trading

NX

NXLNexalin Technology, Inc. Common Stock

NXL

Pay with—

Available Balance0.00

Your PositionYou don't own any NXL yet.

Related Tickers

Earnings